These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31778850)

  • 1. Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    Monteiro A; Rosado P; Rosado L; Fonseca AM; Paiva A
    J Neuroimmunol; 2020 Feb; 339():577113. PubMed ID: 31778850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
    Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
    Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects.
    González-Oria MC; Márquez-Coello M; Girón-Ortega JA; Argente J; Moya M; Girón-González JA
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):413-422. PubMed ID: 30649665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
    Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
    J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Holm Hansen R; Højsgaard Chow H; Sellebjerg F; Rode von Essen M
    Mult Scler; 2019 Aug; 25(9):1289-1297. PubMed ID: 30043661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.
    Rolla S; Bardina V; De Mercanti S; Quaglino P; De Palma R; Gned D; Brusa D; Durelli L; Novelli F; Clerico M
    J Leukoc Biol; 2014 Dec; 96(6):1155-64. PubMed ID: 25097195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients.
    Karimi L; Eskandari N; Shaygannejad V
    Neuroimmunomodulation; 2022; 29(3):177-185. PubMed ID: 34808619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
    Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
    Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.
    Mansilla MJ; Navarro-Barriuso J; Presas-Rodríguez S; Teniente-Serra A; Quirant-Sánchez B; Ramo-Tello C; Martínez-Cáceres EM
    CNS Neurosci Ther; 2019 Sep; 25(9):995-1005. PubMed ID: 31066225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
    Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
    Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.